“Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial”. 2024. SKIN The Journal of Cutaneous Medicine 8 (6): s445. https://doi.org/10.25251/skin.8.supp.445.